PACS Group, Inc. (PACS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

COR gains from strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose risks.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Cencora COR has outperformed the market over the past 10 years by 7.34% on an annualized basis producing an average annual return of 20.01%. Currently, Cencora has a market capitalization of $56.54 billion.

Investors with an interest in Medical Services stocks have likely encountered both Cencora ( COR Quick QuoteCOR - ) and Medpace ( MEDP Quick QuoteMEDP - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.

Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.